| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Type 1 Issues Articles
Symlin Promising as Weight Loss Drug
Oct 12, 2007
Symlin, or pramlintide, is synthetic amylin, a natural hormone that slows stomach emptying and leads to a feeling of fullness. Currently Symlin is used to dampen blood sugar rises in people with diabetes, but it's showing potential as a weight loss drug as well, according to a recent study.
The researchers examined 204 obese subjects for sixteen weeks, half of whom received Symlin injections thrice daily before meals and half of whom were given a placebo on the same schedule.
About 31 percent of the Symlin group lost five percent or more of their weight, compared to only two percent of the placebo group. On average, they lost about eight pounds. Furthermore, 72 percent of them said that their appetite control had improved, versus 31 percent of the placebo group, and 52 percent said their wellbeing had improved, versus only 17 percent of the placebo patients.
Symlin has not yet been approved as a weight loss drug. It is approved as an add-on treatment for people with type 1 who fail to reach glucose control on optimal insulin therapy, or for type 2s who fail to reach glucose control on optimal insulin therapy, with or without concurrent use of metformin or a sulfonylurea. It requires a prescription from your doctor, and insurance often doesn't pay for it. The average wholesale price is about $99 to $179 per month.
Sources: Medline Plus; Journal of Clinical Endocrinology and Metabolism, August 2007
Categories: Professional Issues, Symlin, Type 1 Issues, Type 2 Issues, Weight Loss
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
Oct 12, 2007 -
Email to a Friend
Send a link to this page to your friends and colleagues.